GlassScriptPhysician profile
Charles W Hollen
NPI 1205855723
$10,371.38
in general payments reported to CMS, 2019-2025
52 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,041 · 2020: $926 · 2021: $1,745 · 2022: $2,814 · 2023: $2,796 · 2024: $48.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244 · Education: $435 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,243.78 |
| Education | $434.55 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,681.39 | 2019-2023 | |
| Janssen Biotech, INC. | $939.78 | 2019-2023 | Darzalex, Rybrevant |
| Pfizer INC. | $765.94 | 2019-2023 | |
| Seagen INC. | $726.09 | 2019-2023 | Padcev, Tukysa |
| Astrazeneca Pharmaceuticals LP | $459.67 | 2019-2023 | Lynparza, Enhertu |
| Lilly USA, LLC | $392.91 | 2019-2023 | Verzenio, Jaypirca, Retevmo |
| Amgen INC. | $348.40 | 2020-2023 | Kyprolis, Lumakras, Blincyto |
| E.R. Squibb & Sons, L.L.C. | $319.93 | 2019-2023 | Opdivo |
| Merck Sharp & Dohme LLC | $308.75 | 2019-2023 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $305.38 | 2019-2023 | Venclexta, Perjeta, Phesgo |
| Celgene Corporation | $261.73 | 2019-2023 | Pomalyst, Reblozyl |
| Daiichi Sankyo INC. | $254.47 | 2019-2023 | Enhertu |
| Astellas Pharma US INC | $249.55 | 2019-2023 | Padcev |
| Genzyme Corporation | $234.86 | 2019-2023 | |
| Puma Biotechnology, INC. | $195.78 | 2019-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Hollen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.